EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 208 filers reported holding EXELIXIS INC in Q3 2016. The put-call ratio across all filers is 0.57 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $9,886,890 | -5.7% | 440,004 | -0.4% | 0.01% | -14.3% |
| Q1 2024 | $10,485,148 | +129.2% | 441,852 | +131.7% | 0.01% | +133.3% |
| Q4 2023 | $4,575,517 | -85.1% | 190,726 | -86.5% | 0.00% | -87.5% |
| Q3 2023 | $30,810,969 | +50.4% | 1,410,113 | +31.5% | 0.02% | +60.0% |
| Q2 2023 | $20,487,678 | -20.3% | 1,072,092 | -19.1% | 0.02% | -25.0% |
| Q1 2023 | $25,711,068 | +47.4% | 1,324,630 | +21.8% | 0.02% | +42.9% |
| Q4 2022 | $17,443,195 | -1.9% | 1,087,481 | -4.1% | 0.01% | -12.5% |
| Q3 2022 | $17,784,000 | -65.6% | 1,134,206 | -54.3% | 0.02% | -61.9% |
| Q2 2022 | $51,633,000 | +33.5% | 2,479,977 | +45.3% | 0.04% | +61.5% |
| Q1 2022 | $38,681,000 | +4037.0% | 1,706,245 | +3235.4% | 0.03% | +2500.0% |
| Q4 2021 | $935,000 | -94.2% | 51,155 | -93.3% | 0.00% | -90.9% |
| Q3 2021 | $16,095,000 | -36.3% | 761,333 | -45.1% | 0.01% | -35.3% |
| Q2 2021 | $25,263,000 | +2141.6% | 1,386,566 | +2679.6% | 0.02% | +1600.0% |
| Q1 2021 | $1,127,000 | +242.6% | 49,883 | +204.8% | 0.00% | – |
| Q4 2020 | $329,000 | -97.5% | 16,368 | -97.0% | 0.00% | -100.0% |
| Q3 2020 | $13,132,000 | +18.7% | 537,096 | +15.2% | 0.01% | +20.0% |
| Q2 2020 | $11,067,000 | +230.1% | 466,159 | +139.4% | 0.01% | +150.0% |
| Q1 2020 | $3,353,000 | +102.7% | 194,740 | +107.5% | 0.00% | +100.0% |
| Q4 2019 | $1,654,000 | -93.6% | 93,861 | -93.6% | 0.00% | -92.3% |
| Q3 2019 | $25,902,000 | -16.9% | 1,464,637 | +0.4% | 0.03% | -16.1% |
| Q2 2019 | $31,167,000 | -10.9% | 1,458,428 | -0.8% | 0.03% | -11.4% |
| Q1 2019 | $34,984,000 | +0.5% | 1,469,929 | -16.9% | 0.04% | -12.5% |
| Q4 2018 | $34,795,000 | -20.9% | 1,768,928 | -28.7% | 0.04% | -7.0% |
| Q3 2018 | $43,984,000 | +0.5% | 2,482,162 | +22.0% | 0.04% | -2.3% |
| Q2 2018 | $43,777,000 | +487.5% | 2,034,270 | +504.6% | 0.04% | +450.0% |
| Q1 2018 | $7,452,000 | -83.3% | 336,448 | -77.1% | 0.01% | -82.2% |
| Q4 2017 | $44,686,000 | +560.4% | 1,469,945 | +426.4% | 0.04% | +542.9% |
| Q3 2017 | $6,766,000 | -11.7% | 279,254 | -10.3% | 0.01% | -12.5% |
| Q2 2017 | $7,665,000 | -40.6% | 311,208 | -47.7% | 0.01% | -38.5% |
| Q1 2017 | $12,895,000 | +31.4% | 595,040 | -9.6% | 0.01% | +18.2% |
| Q4 2016 | $9,815,000 | +332.2% | 658,250 | +270.6% | 0.01% | +450.0% |
| Q3 2016 | $2,271,000 | -20.8% | 177,599 | -51.6% | 0.00% | -33.3% |
| Q2 2016 | $2,866,000 | +117.1% | 366,922 | +11.2% | 0.00% | +50.0% |
| Q1 2016 | $1,320,000 | -26.3% | 329,916 | +3.9% | 0.00% | 0.0% |
| Q4 2015 | $1,790,000 | +6.7% | 317,438 | +6.1% | 0.00% | 0.0% |
| Q3 2015 | $1,678,000 | +187.8% | 299,114 | +81.8% | 0.00% | +100.0% |
| Q1 2014 | $583,000 | -46.1% | 164,572 | -6.8% | 0.00% | 0.0% |
| Q4 2013 | $1,082,000 | +5.3% | 176,572 | 0.0% | 0.00% | 0.0% |
| Q3 2013 | $1,028,000 | +36.5% | 176,572 | +6.4% | 0.00% | 0.0% |
| Q2 2013 | $753,000 | – | 165,892 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
| GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
| Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
| CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
| EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
| CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
| Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
| FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
| Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |